Elshimy Ghada, Correa Ricardo
Endocrinology, Diabetes and Metabolism, University of Arizona College of Medicine-Phoenix, Phoenix, USA.
Cureus. 2019 Aug 21;11(8):e5448. doi: 10.7759/cureus.5448.
Euglycemic diabetic ketoacidosis (DKA) is a known complication of sodium-glucose co-transporter 2 (SGLT-2) inhibitors that have been reported in the literature. The prevalence of this side effect is growing and the exact mechanism of action on why this happens is unknown. Hypoglycemia events are very rare in diabetic patients using SGLT-2 inhibitors and/or metformin when they have normal kidney function. We report a novel complication of hypoglycemia that occurred during the course of treatment of SGLT2 inhibitor-induced DKA in a patient with type 2 diabetes mellitus (T2DM) on the dapagliflozin-metformin combination.
正常血糖性糖尿病酮症酸中毒（DKA）是文献中已报道的钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂的一种已知并发症。这种副作用的发生率正在上升，而其发生的具体作用机制尚不清楚。当糖尿病患者肾功能正常时，使用SGLT-2抑制剂和/或二甲双胍时低血糖事件非常罕见。我们报告了1例2型糖尿病（T2DM）患者在使用达格列净-二甲双胍联合治疗SGLT2抑制剂诱导的DKA过程中发生低血糖这一罕见并发症。
